Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Apple : J&J Opens Enrollment for 'Heartline' Study in Collaboration With Apple

share with twitter share with LinkedIn share with facebook
share via e-mail
02/25/2020 | 09:03am EST

By Colin Kellaher

 

Johnson & Johnson on Tuesday said it has opened enrollment for "Heartline," a study in collaboration with Apple Inc. that will explore if a new iPhone app and heart-health features on the Apple Watch can help reduce the risk of stroke.

J&J said U.S. adults 65 years and older can join the study by downloading the Heartline Study app on an iPhone.

The company said the study will assess whether the Heartline app and the ECG app and irregular rhythm notification feature on the Apple Watch can reduce the likelihood of stroke and improve health outcomes with earlier detection of atrial fibrillation, a common form of irregular heart rhythm that is a leading cause of stroke.

J&J and Apple early last year announced plans to collaborate on the earlier detection of atrial fibrillation.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
09:03aAPPLE : J&J Opens Enrollment for 'Heartline' Study in Collaboration With Apple
DJ
08:26aJOHNSON & JOHNSON : Launches Heartline™, the First-of-its-Kind, Virtual St..
PR
02/24J&J, Sanofi, Inovio Hunt for Coronavirus Vaccines
DJ
02/24JOHNSON & JOHNSON : Ex-dividend day for
FA
02/19JOHNSON & JOHNSON : to Expand Partnership with U.S. Department of Health and Hum..
AQ
02/19JOHNSON & JOHNSON : to Participate in Cowen 40th Annual Health Care Conference
AQ
02/18JOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATION..
AQ
02/18Sanofi to Work on Coronavirus Vaccine
DJ
02/18JOHNSON & JOHNSON : Expands Partnership With HHS to Find Coronavirus Treatment
DJ
02/18JOHNSON & JOHNSON : to Expand Partnership with U.S. Department of Health & Human..
PU
More news
Financials (USD)
Sales 2020 85 861 M
EBIT 2020 27 634 M
Net income 2020 19 976 M
Finance 2020 322 M
Yield 2020 2,75%
P/E ratio 2020 19,8x
P/E ratio 2021 16,7x
EV / Sales2020 4,47x
EV / Sales2021 4,22x
Capitalization 384 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 160,00  $
Last Close Price 145,91  $
Spread / Highest target 18,6%
Spread / Average Target 9,66%
Spread / Lowest Target -8,85%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.78%384 432
ROCHE HOLDING AG10.13%290 942
NOVARTIS2.72%211 608
MERCK AND COMPANY-10.58%207 065
PFIZER-8.83%191 868
NOVO NORDISK AS13.46%145 457